Detalles de la búsqueda
1.
Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).
Hematol Oncol
; 36(1): 202-209, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28681529
2.
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Acta Haematol
; 134(1): 25-31, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25871926
3.
An autopsy case of chronic active Epstein-Barr virus infection (CAEBV): distribution of central nervous system (CNS) lesions.
J Neurol Sci
; 275(1-2): 170-7, 2008 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18793782
4.
[Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].
Rinsho Byori
; 56(7): 570-6, 2008 Jul.
Artículo
en Japonés
| MEDLINE | ID: mdl-18709988
5.
Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification.
Leuk Res
; 28(12): 1287-92, 2004 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-15475070
6.
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.
Int J Hematol
; 93(5): 618-623, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21523339
Resultados
1 -
6
de 6
1
Próxima >
>>